After finishing at $3.13 in the prior trading day, Trevi Therapeutics Inc (NASDAQ: TRVI) closed at $2.88, down -8.13%. In other words, the price has decreased by -$0.2550 from its previous closing price. On the day, 554225 shares were traded. TRVI stock price reached its highest trading level at $3.1900 during the session, while it also had its lowest trading level at $2.8300.
Ratios:
Our goal is to gain a better understanding of TRVI by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.03 and its Current Ratio is at 15.03. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, B. Riley Securities on April 12, 2023, initiated with a Buy rating and assigned the stock a target price of $6.
On November 22, 2022, SVB Leerink started tracking the stock assigning a Outperform rating and target price of $6.
On June 03, 2019, SVB Leerink started tracking the stock assigning a Outperform rating and target price of $14.SVB Leerink initiated its Outperform rating on June 03, 2019, with a $14 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 11 ’23 when Delfini Lisa sold 785 shares for $2.02 per share. The transaction valued at 1,586 led to the insider holds 35,901 shares of the business.
Delfini Lisa sold 711 shares of TRVI for $1,564 on Sep 11 ’23. The Chief Financial Officer now owns 34,394 shares after completing the transaction at $2.20 per share. On Aug 11 ’23, another insider, Delfini Lisa, who serves as the Chief Financial Officer of the company, sold 682 shares for $2.36 each. As a result, the insider received 1,610 and left with 32,814 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TRVI now has a Market Capitalization of 198.61M and an Enterprise Value of 116.97M.
Stock Price History:
Over the past 52 weeks, TRVI has reached a high of $4.00, while it has fallen to a 52-week low of $0.97. The 50-Day Moving Average of the stock is 2.6702, while the 200-Day Moving Average is calculated to be 2.0487.
Shares Statistics:
The stock has traded on average 298.25K shares per day over the past 3-months and 349.74k shares per day over the last 10 days, according to various share statistics. A total of 68.28M shares are outstanding, with a floating share count of 44.06M. Insiders hold about 36.11% of the company’s shares, while institutions hold 43.63% stake in the company. Shares short for TRVI as of Mar 15, 2024 were 1.07M with a Short Ratio of 3.59, compared to 1.19M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.57% and a Short% of Float of 2.17%.
Earnings Estimates
Its stock is currently analyzed by 5 different market analysts. On average, analysts expect EPS of -$0.09 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.09, while EPS last year was -$0.06. The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.09 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.32 and -$0.45 for the fiscal current year, implying an average EPS of -$0.39. EPS for the following year is -$0.45, with 5 analysts recommending between -$0.33 and -$0.6.
